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Abstract  
Zinc transporter, ZRT- and IRT-like protein 4 (ZIP4), seems related to tumor progression in 
some cancers. Here we found up-regulated ZIP4 in oral squamous cell carcinomas (OSCCs) 
compared with normal counterparts, ZIP4 expression positively correlated with tumor size, 
and decreased intercellular zinc and cell growth in ZIP4 knockdown cells (P<0.05). 
Furthermore, the greater cell growth after ZnCl2 treatment suggested the impact of 
intercellular Zinc accumulation on tumor growth. Consistent with this, decreased zinc uptake 
by ZIP4 knockdown and a chelating agent inhibited cell proliferation. Thus, ZIP4 and 
intracellular zinc are essential to tumor growth, making zinc a potential therapeutic target for 
OSCCs. 
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Introduction 
Zinc is an essential element in the human body that regulates numerous physiologic 
processes. Free zinc is important because it can easily exchange between different cellular 
compartments and bind to numerous proteins, leading to activation of biologic functions [1]. 
Zinc also is stored and released from intracellular vesicular compartments and functions as an 
intracellular second messenger [2, 3].  
ZRT- and IRT-like protein (ZIP) transporter increase intracellular zinc by promoting 
uptake of zinc from the extracellular space and vesicular zinc release to the cytosol. Fourteen 
human ZIP transporters that are thought to facilitate zinc influx into the cytosol [4] have been 
reported thus far. Of them, ZIP4 plays an important function in maintaining an intracellular 
zinc level by the uptake of nourishment zinc from intestinal epithelium cells and release of 
zinc from the vesicular compartments [5]. ZIP4 also regulates the activities of the cyclic 
adenosine monophosphate response element-binding protein and zinc finger transcription 
factors [6]. 
 ZIP4 is up-regulated in pancreatic and hepatocellular cancers and promotes the cell-
cycle, cell proliferation, and invasiveness [5, 7]. Down-regulated ZIP4 increases the survival 
rate in pancreatic cancer xenografts [8]. In contrast, ZIP4 expression is low in prostate cancer 
cells, and overexpressed ZIP4 reduces cellular migratory activity [9]. Thus, ZIP4 plays 
pivotal functions in development and progression of several types of cancer. 
We report the results of the critical analyses of the molecular subtypes of ZIP4 in oral 
squamous cell carcinoma (OSCC) contributing to tumor progression of OSCCs clinically 
here. 
  
                         
 
Materials and methods 
Ethical statement 
The ethical review board of Chiba University approved the protocol (protocol number, 
236) for this study. 
 
OSCC cell lines and tissue samples 
We purchased Ho-1-N-1 (JCRB-0831, buccal mucosa), KOSC-2 (JCRB-0126.1, mouth 
floor), SAS (RBRC-RCB 1974, tongue), HSC-2 (RBRC-RCB1945, mouth), HSC-3 
(JCRB-0623, tongue), HSC-4 (RBRC-RCB1902, tongue), Ho-1-u-1 (RBRC-RCB2102, 
mouth floor), Ca9-22 (RCB-1976, gingiva), and Sa3 (RBRC-RCB0980, upper gingiva) 
cell lines, derived from human OSCCs, from the JCRB cell bank (Ibaraki, Osaka, Japan) 
or cell bank of RIKEN BioResource Center (Tsukuba, Ibaraki, Japan). Normal oral 
keratinocytes (HNOKs) as previously described [9-15] used as normal control cells. 
 
mRNA expression analysis 
Total RNA extraction and cDNA generation were performed as described previously [10, 
15]. As previously described, qRT-PCR (quantitative Real-Time PCR) was conducted [9-
11, 16-19]. The sequences primers were used: ZIP4, 5’-GCTCCAGTGTGTGGGACA-3’ 
and 5’-GCCTGTTCCGACAGTCCA-3’ and universal probe #46. 
 
Immunoblotting analysis 
Protein extraction and immunoblotting analysis were conducted as described previously 
[16-19]. The antibodies were anti-ZIP4 (LifeSpan BioSciences, Seattle, WA, USA), anti-
GAPDH (sc-32233; mouse, 6C5 or sc-25778; rabbit, FL-335), anti-p21 (sc-397; rabbit, 
                         
 
C-19), anti-cyclin D1 (sc-20044; mouse, DCS-6), anti-cyclin E (sc-377100; mouse, E-4) 
(Santa Cruz Biotechnology; SCB, Santa Cruz CA, USA), anti-CDK2 (#2546; rabbit, 
78B2), anti-CDK4 (#12790; rabbit, D9GE3), and anti-CDK6 (#13331; rabbit, D4S8S), 
anti-p27KIP1 (#3698; mouse, SX53G8.5), (Cell Signaling Technology, Danvers, MA, 
USA).  
 
IHC 
As previously described, IHC and IHC scoring system were performed [20-24]. In order 
to decide a cut-off points of the ZIP4 IHC scores of the clinical parameters, we evaluated 
the OSCCs IHC scores from 100 samples by Receiver Operating Characteristic  curve 
(ROC) analysis by EZR software [25]. Cases with a score over the cutoff point were 
defined as ZIP4-positive. 
 
Transfection with shRNA plasmid 
ZIP4 shRNA (shZIP4) or control shRNA (shMock) vectors were purchased from Santa 
Cruz Biotechnology. The two OSCC-derived cell lines (Ca9-22 and Sa3) were 
transfected with shZIP4 or shMock vectors using Lipofectamine 3000 Transfection 
Reagent (Thermo Fisher Scientific, Waltham, MA, USA). 
 
Cell growth 
As previously described, we analyzed cell growth in the shZIP4 and shMock cells to 
evaluate the effect of the ZIP4 knockdown on cell growth [10, 15]. 
 
Zinc staining 
                         
 
To evaluate zinc uptake, we stained shZIP4 and shMock cells for zinc. Briefly, these cells 
were seeded in 6-cm dishes at a density of 1×104 viable cells after serum starvation for 24 
hours. Before the assay, shZIP4 and shMock cells were treated with the membrane-
permeable zinc chelator, N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN, 4 
μM), at 37 °C for 1 hour to remove intracellular zinc [8, 26]. After washing with PBS, the 
cells were grown in the culture medium with 5 μM of ZnCl2 for 96 hours. The cells were 
incubated in the zinc-deficient medium containing 25 μM of Zinquin, a zinc-specific 
fluorescent dye (Dojindo Laboratories, Kamimasuki, Kumamoto, Japan) at 37 °C for 30 
minutes, and photographed using a digital Nikon Eclipse TE2000-U (Nikon, Minatoku, 
Tokyo, Japan) [27-31]. 
 
Cell-cycle analysis 
To synchronize cells of the G0/G1 or G2/M transition, as previously described, cell-cycle 
analysis was conducted [16-19, 32, 33].  
 
Zinc treatment and cell growth 
To investigate the effect of zinc on cell proliferation, we performed cell growth assays for 
shZIP4 and shMock cells after treatment with ZnCl2. Briefly, the cells were seeded in 6-
cm dishes at a density of 1×104 viable cells after serum starvation for 24 hours. The cells 
were treated with TPEN (4 μM) at 37 °C for 1 hour. After washing with PBS (phosphate 
bufferes saline) to remove excess TPEN, the cells were incubated with DMEM in the 
presence of 0- to 10 μM of ZnCl2 for the indicated time. 
 
Statistical analysis 
                         
 
The statistical significance was determined using the Mann-Whitney U-test. 
Relationships between the ZIP4 IHC scores and clinicopathological profiles were 
analysed using the Mann-Whitney U-test and Student’s t-test. 
  
                         
 
Results 
Evaluation of ZIP4 mRNA and protein expression in OSCC-derived cell lines and 
primary OSCCs 
To investigate the status of ZIP4 expression, we performed qRT-PCR and 
immunoblotting analyses using nine OSCC-derived cell lines and HNOKs. ZIP4 mRNA 
was up-regulated significantly in all cell lines compared with the counterpart (Fig. 1A, 
P<0.05). ZIP4 protein expression also significantly increased in all cell lines compared 
with the counterpart (Fig. 1B, P<0.05). Strong ZIP4 immunoreactivity was detected in the 
cell membrane and cytoplasm of primary OSCCs; however, normal oral tissues showed 
almost weak immunoreactivity (Fig. 1C-1). The ZIP4 IHC scores in OSCCs and adjacent 
normal oral tissues ranged from 46 to 196 (median, 117.50) and 3 to 78 (median, 27.50). 
We showed representative IHC data for ZIP4 protein in normal oral tissue and primary 
OSCCs (Fig. 1C-2, -3). We used ROC curve analysis in order to determine the optimal 
cutoff point from the IHC scores (Fig. 1D). This data showed that the area under the 
curve (AUC) was 0.7115 (95% confidence interval, 0.5541-0.869) and the cutoff value 
was 117.0. ZIP4-positive OSCCs were associated significantly with the primary tumor 
size among the clinical parameters (Fig. 1E, P<0.05). 
 
Establishment of ZIP4 knockdown cells 
shZIP4 or shMock vectors were used for the transfections into two OSCC cell lines 
(Ca9-22 and Sa3) because up-regulation of ZIP4 was frequently observed in OSCC-
derived cells (Fig. 1A, B). qRT-PCR and immunoblotting analyses showed that the ZIP4 
mRNA and protein expression levels in shZIP4 cells were significantly lower than that in 
shMock cells (Fig. 2A, B, respectively; P<0.05). 
                         
 
 
Cell growth of ZIP4 knockdown cells 
To investigate the effect of ZIP4 knockdown on cell proliferation, we performed a cell growth 
assay that showed that the cell growth in shZIP4 cells were lower than that in shMock cells 
(Fig. 2C, P<0.05).  
 
Accumulation of zinc in ZIP4 knockdown cells 
Zinc fluorescent imaging was performed to assess the accumulation of intracellular zinc in 
shZIP4 and shMock cells. Cytosolic fluorescence was observed in the shMock cells after 
treatment with ZnCl2 (5 µM) for 96 hours, whereas fainter fluorescence was observed in 
shZIP4 cells (Fig. 2D). 
 
Cell-cycle analysis of shZIP4 cells 
We assessed the cell-cycle distribution by flow cytometers (Accuri C6) because the cell 
growth of the ZIP4 knockdown cells decreased. The number of shZIP4 cells of the G1 phase 
was significantly greater than in shMock cells (Fig. 2E, P<0.05). These results indicated that 
shZIP4 inhibited cell proliferation by cell-cycle arrest of the G1 phase. When we assessed the 
expression levels of the cyclin-dependent kinase inhibitors (CDKIs) (p21Cip1 and p27Kip1), 
cyclins, and CDKs, the CDKIs were up-regulated, and cyclin D1, cyclin E, CDK2, CDK4, 
and CDK6 were down-regulated in the shZIP4 cells (Fig. 2F). 
 
Cell growth after zinc treatment in a dose-dependent manner  
Before the cell proliferation assay, we treated the cells with TPEN to remove intercellular 
zinc. The cells then were cultured in the medium with the indicated concentrations of ZnCl2 
                         
 
(0-10 μM) for 96 hours. The optimal concentration was determined to be 5 μM of ZnCl2, 
because there was no cell growth in the 10-μM ZnCl2 treatment (Fig. 3A). There was no 
significant difference in cell growth between the shMock and shZIP4 cells without ZnCl2 
treatment (Fig. 3B). The cell growth of the shMock cells was significantly greater than that of 
the shZIP4 cells after ZnCl2 treatment (Fig. 3C). The data indicated that intracellular zinc 
plays a critical role in cell growth. 
 
Cellullar growth after TPEN treatment 
To examine the effect of TPEN on the cell growth in the shMock and shZIP4 cells, the cells 
were treated with TPEN (4 µM) for 1 hour before the cell proliferation assays (0 or 5 µM 
ZnCl2; 96 hours). After treatment with TPEN, the number of cultured cells decreased 
dramatically in the zinc depletion medium (FBS-, TPEN+, ZnCl2-) compared with control 
cultures (Fig. 4, P<0.05). However, the cell growth increased significantly in the 5-µM ZnCl2 
medium (FBS-, TPEN+, ZnCl2+). The data indicated that depletion of intercellular and 
extracellular zinc led to inhibited cell growth. 
  
                         
 
Discussion 
The present study provided the first evidence that ZIP4 up-regulation occurs in OSCCs and is 
positively correlated with tumor size. ZIP4 knockdown experiments also showed that ZIP4 
controlled cell proliferation by arresting cell-cycle progression of the G1/S phase, suggesting 
that ZIP4 plays an important role in tumor size in human OSCCs. Depletion of intracellular 
zinc using TPEN, a chelating agent, showed similar results to the ZIP4 knockdown 
experiment (Fig. 5). 
ZIP4 knockdown cells not only had less intracellular zinc (Fig. 2D) but also low cell 
growth activity (Fig. 2C). Zinc deficiency is related to diverse disorders, such as an impaired 
immune response; retardation of growth, wound healing, and skeletal development [5, 34]; 
and decreased activity of deoxythymidine kinase associated with DNA synthesis. A previous 
study reported that zinc was required for accumulation and maintenance of a protein that 
mediated cellular entry into the cell-cycle of the S phase [35]. Our data also showed cell-
cycle arrest of the G1/S phase (Fig. 2E) in shZIP4 cells, suggesting that zinc, the target of 
ZIP4, plays an essential role in cell proliferation. The concentration of intracellular free zinc 
is strictly regulated, which is known as zinc homeostasis [36]. However, the mechanisms 
responsible for regulating zinc homeostasis are not well established. Since previous studies 
have indicated that zinc transport and metabolism are related to progression of cancer [37, 
38], our TPEN treatment might be a new therapeutic tool for several types of cancers, 
including OSCCs. Further studies are warranted to elucidate the zinc network and the effects 
of zinc on storage and release on target protein regulation in OSCCs. 
 Previous studies have reported that liver cancers have high ZIP4 expression and low 
zinc levels in the tumor tissues; however, prostate cancers have low ZIP4 expression and low 
zinc levels in the tumor tissues [7, 39-41]. This apparent difference between those studies 
                         
 
might be due to different tissue and organ sites, which have different mechanisms of zinc 
uptake. Therefore, further studies are needed to study the ZIP4 pathway in the cancer 
microenvironment.  
In conclusion, the present study explored the molecular function of ZIP4 in oral cancer. 
Our data indicated that overexpression of ZIP4 might directly affect tumor growth in OSCCs 
and that ZIP4 is a potential biomarker of aggressive tumor progression and a potential 
therapeutic target for OSCCs. In addition, zinc depletion by ZIP4 knockdown and TPEN 
treatment showed dramatic inhibitory effects on cell growth in oral cancer. Thus, the zinc 
metabolism plays an active part as a new target for cancer progression. 
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Legends 
Fig. 1. Evaluation of ZIP4 expression in OSCC-derived cell lines and primary OSCCs.  
(A) Quantification of ZIP4 mRNA expression in OSCC-derived cell lines by qRT-
PCR analysis. The data are expressed as the mean ± SEM of triplicate results 
(✽P<0.05, Student’s t-test). (B) Immunoblotting analysis of ZIP4 protein in OSCC-
derived cell lines and HNOKs. Densitometric ZIP4 protein data are normalized to the 
GAPDH protein levels. The values are expressed as a percentage of the HNOKs. (C-
1) ZIP4 status in primary OSCCs (n=100) and normal counterparts by the IHC 
(*P<0.05, Student’s t-test). Representative IHC data of normal oral tissue (C-2) and 
OSCC (C-3). (D, E) ROC curve analysis shows that the optimal cutoff point is 117.0 
(AUC, 0.7115; 95% CI, 0.554-0.869; sensitivity, 73.1%; specificity, 66.7%). ZIP4 
protein expression in primary OSCCs differs significantly (P=0.0209, Student’s t-test) 
between T1+T2 and T3+T4. 
 
Fig. 2. Phenotypes of ZIP4 knockdown cells. (A, B) Expression of ZIP4 mRNA and 
protein in shZIP4 and shMock cells (✽P<0.05, Student’s t-test). (C) Cell growth assay of 
shZIP4 and shMock cells. The data are expressed as the mean ± SEM of triplicate results 
(*P<0.05, Student’s t-test). (D) To monitor intracellular zinc, the cells are stained with 
Zinquin ester, a zinc-specific fluorescence dye, after treatment with 5μM ZnCl2 for 96 
hours. The accumulation of intracellular zinc in the shZIP4 cells is significantly lower than 
that in the shMock cells. (E) Flow cytometric analysis is performed to investigate cell-cycle 
progression in the shZIP4 and shMock cells after synchronization at the G2/M phase using 
nocodazole. (F) Immunoblotting analysis shows up-regulation of p21Cip1 and p27Kip1 and 
down-regulation of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 in the shZIP4cells 
                         
 
compared with the shMock cells. 
 
Fig. 3. Effect of zinc on cell growth. (A) Determination of the optimal concentration for cell 
growth. The shMock and shZIP4 cells were cultured in the medium with the indicated 
concentrations of ZnCl2 (0-10 μM) for 96 hours. In shMock cells, 5 μM ZnCl2 is the most 
effective concentration for cell growth. (B, C) Cell growth with and without zinc. There is no 
difference of cell growth between shMock and shZIP4 cells without ZnCl2 treatment. The 
cell growth of the shMock cells is significantly higher than that of the shZIP4 cells in the 5-
μM ZnCl2 medium. The data are expressed as the mean ± SEM of triplicate results 
(*P<0.05). 
 
Fig 4. Cell growth after TPEN treatment. The cells in the 6-cm dishes (1×104 cells/dish) 
were treated with 4 μM of TPEN for 1 hour at 37°C, washed with PBS, and incubated in 
the culture medium with 5 µM ZnCl2 for 96 hours. The data are expressed as the mean 
± SEM of triplicate results (*P<0.05). After treatment with TPEN, the number of 
cultured cells decreases dramatically in the zinc-depleted medium (FBS-, TPEN+, 
ZnCl2-) compared with control cultures, whereas a significant increase in cell growth is 
seen in the 5-µM ZnCl2 medium (FBS-, TPEN+, ZnCl2+). These data indicate that 
depletion of intercellular and extracellular zinc led to inhibited cell growth. 
 
Fig 5. The effect of zinc in ZIP4 and TPEN treatment. ZIP4-positive OSCC 
overexpression causes increased levels of intracellular zinc and cell growth compared 
with ZIP4-negative OSCC cells. ShZIP4 cells decrease zinc uptake and cell growth. 
After chelation for zinc with TPEN, the cell growth decreases. 
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